Education about Non-Alcoholic Steatohepatitis (NASH) and the Role of PPAR Agonists
Link Between NAFLD and Heart Failure – A Cardiology Perspective
Join Dr Marat Fudim in this webinar as he delves into the complex interplay between
Multistakeholder Approach to Innovations in NAFLD Care
Discover the importance of a multistakeholder approach in NAFLD care, addressing the challenges of comorbidities,
The Odyssey for an Optimal NASH Biomarker: Challenges and Opportunities in 2023
Explore the challenges and opportunities in the quest for a non-invasive diagnosis tool of non-alcoholic
NAFLD Pathophysiologic Role of Intrahepatic Vasculature
Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease
Discover all about NASH, NAFLD PPAR agonists ⟶
Link Between NAFLD and Heart Failure – A Cardiology Perspective Slide
Join Dr Marat Fudim in this webinar as he delves into the complex interplay between non-alcoholic fatty liver disease (NAFLD)
Multistakeholder Approach to Innovations in NAFLD Care Slides
Explore with the slides the significance of a multistakeholder approach in NAFLD care as it tackles the complexities of comorbidities,
NAFLD Pathophysiologic Role of Intrahepatic Vasculature Slides
Dr. Kwanten (Belgium) discusses the role of pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions
Improving NASH clinical trials: barriers and breakthroughs
Despite its global prevalence of 25%, no pharmacotherapies have yet been approved to treat non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), its inflammatory subtype.
From NAFLD to NASH: determining disease progression and regression rates
The spectrum of non-alcoholic fatty liver disease (NAFLD) is divisible into three stages: 1) NAFL, 2) non-alcoholic steatohepatitis (NASH), NAFLD’s progressive and inflammatory subtype, and 3) NAFLD or NASH with fibrosis, whose stages range from F0-4.
The power of PPARs in NASH-associated microvascular dysfunction
Hepatic microvascular dysfunction is central to the development and progression of nonalcoholic steatohepatitis (NASH), the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD).
Phospholipid depletion and NAFLD pathophysiology: findings from lipidomics
Along with its association with metabolic syndrome, NAFLD is closely linked with mixed dyslipidaemia (reduced high-density lipoprotein cholesterol (HDL-C) and increased very low-density lipoprotein triglycerides (VLDL-TG)).
New this week!
Link Between NAFLD and Heart Failure – A Cardiology Perspective
Join Dr Marat Fudim in this webinar as he delves into the complex interplay between non-alcoholic fatty liver disease (NAFLD) and heart failure. Uncover the paramount importance of
EDITOR OF THE MONTH!
Dr. Jörn M. Schattenberg is a renowned hepatology expert and professor. He leads the Gastroenterology and Hepatology Division at Miami VA Healthcare System, with a research focus on liver disease mechanisms. A dedicated educator, he mentors future hepatologists.
Latest Research toward the treatment of NASH disease
Knowledge is crucial for healthcare professionals to manage and diagnose patients with NASH and NAFLD. Over the years, we have been increasingly communicating the results achieved by research, showcasing the latest on therapy to diagnosis and management.
LATEST SCIENTIFIC ADVANCES IN NASH, NAFLD & PPAR AGONISTS
Non-Invasive Assessment of cACLD and Portal Hypertension
Dr. Jörn Schattenberg (Germany) analyses the latest on the assessment in cirrhosis along with his
Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications
Fibrosis is an independent predictor of liver-related mortality but rarely if ever occurs without NASH
Burden of Liver-Related Comorbidities in Cardiovascular Disease
In this video Prof. Sven Francque explores that NAFLD is prevalent in patients with cardiovascular
How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and
HCC Pathogenesis in NASH and the Impact of Fibrosis
Dr. Scott Friedman talks about HCC pathogenesis in NASH and the impact of fibrosis. This
Natural history & clinical outcomes in adults with NAFLD
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic
The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in
NASH Treatment in 2022: Review of Current and Future Therapies for Non-Alcoholic Steatohepatitis
Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of
NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise
Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in
Noninvasive tests for NAFLD: where are we now?
Cardiovascular disease in MAFLD versus NAFLD: a review
CATEGORIES
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES
Latest articles from PubMed
- Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions June 1, 2023
- Non-Alcoholic Fatty Liver Disease and Diabetes: the bad marriage June 1, 2023
- Estimation of non-alcoholic steatohepatitis (NASH) disease using clinical information based on the optimal combination of intelligent algorithms for feature selection and classification May 31, 2023
- Association of serum uric acid-to-high-density lipoprotein cholesterol ratio with non-alcoholic fatty liver disease in American adults: a population-based analysis May 31, 2023
- Prevalence of metabolic associated fatty liver disease (MAFLD) in patients with gallstone disease. Study on a cohort of cases in South-Southeastern Mexico May 31, 2023
- Non-alcoholic fatty liver disease in patients with chylomicronemia syndromes May 31, 2023
- INASL-SAASL Consensus Statements on NAFLD Name Change to MAFLD May 30, 2023
- The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States May 30, 2023
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.